Insider Activity at Core Scientific Inc. – A Closer Look at the Latest Transaction

The Current Deal: A Restricted‑Stock Unit Grant for CFO James Nygaard On May 20 2026, Core Scientific Inc. disclosed that Chief Financial Officer James Nygaard received a grant of 120,074 restricted‑stock units (RSUs). The grant is structured to vest in one‑third on March 15 2027 and the remaining two‑thirds over eight quarterly installments thereafter, contingent on continued service. The transaction is a “buy” under SEC terminology because it represents a new award, not a market purchase, and the units carry no immediate cash price (price listed as $0.00). At the time of filing, Nygaard’s post‑transaction holdings rose to 1,043,056 shares, up from roughly 923,000 shares following two significant sales earlier in March.

Implications of the RSU Grant Amid a Volatile Insider Landscape The RSU award signals management’s confidence in Core Scientific’s future trajectory, particularly given the company’s recent 4.38 % weekly gain and 19.25 % monthly rally. However, the timing coincides with a flurry of sales by other insiders, notably Todd DuChene and CEO Adam Taylor. DuChene’s May 18 sale of 9,600 shares at $23.12 and several smaller sales in the preceding weeks suggest a tactical off‑loading of inventory, perhaps to diversify holdings or fund other ventures. For investors, the dual pattern—executive sales coupled with RSU awards—may indicate a balancing act: insiders are liquidating portions of their positions while still aligning long‑term interests through vesting schedules.

What This Means for Investors and Core Scientific’s Future The company’s market cap of $7.29 billion and a negative P/E of –6.83 underscore a valuation that is still relatively discounted compared to peers in the AI and blockchain space. The recent RSU grant could be interpreted as a management bet on the company’s ability to unlock value, especially as Core Scientific continues to expand its AI infrastructure services. Yet, the sales by senior officers could raise concerns about short‑term pressure on the share price. If insider selling persists while the company delivers on its growth roadmap—particularly in managed hosting and digital asset self‑mining—price resilience could be reinforced. Conversely, a sustained outflow might erode confidence, especially if coupled with any negative news or earnings misses.

A Profile of James Nygaard: From Seller to Beneficiary Nygaard’s insider history shows a pattern of selling substantial blocks in March 2026—selling 92,725 shares on March 17 and 98,671 shares on March 26, reducing his holdings to roughly 928,000 and 923,000 shares respectively. These sales were priced at $16.42 per share, indicating a willingness to liquidate at levels well below the current market price of $24.82. The recent RSU grant flips the script: instead of cashing out, Nygaard is now being granted new equity that will vest over time, aligning his interests with the long‑term success of Core Scientific. The shift from liquid sales to restricted awards suggests a strategic recalibration—perhaps reflecting increased confidence in the company’s prospects or a change in personal investment strategy.

Balancing Short‑Term Liquidity and Long‑Term Commitment For seasoned investors, the insider activity signals a nuanced narrative. On one hand, the CFO’s prior sales may have been motivated by personal diversification or risk management. On the other, the RSU grant—especially given its vesting structure—reaffirms management’s commitment to the company’s future. Coupled with the broader insider activity—most notably DuChene’s large block of 138,547 shares bought on May 20 after selling earlier—this pattern reflects a sophisticated dance between liquidity needs and long‑term alignment. As Core Scientific continues to navigate the fast‑evolving AI and blockchain sectors, monitoring these insider movements will be essential for gauging management confidence and potential future price dynamics.

DateOwnerTransaction TypeSharesPrice per ShareSecurity
2026-05-20Nygaard James P Jr (EVP, Chief Financial Officer)Buy120,074.00N/ACommon Stock
2026-05-20DUCHENE TODD M (See remarks)Buy138,547.00N/ACommon Stock